Navigation Links
Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
Date:9/22/2007

ENGLEWOOD, Colo., Sept. 21 /PRNewswire/ -- Baxa Corporation, a leading provider of systems for safe fluid handling and delivery in hospital pharmacies, announces the addition of two new international product distributors. These agreements -- with Magallan Pharma Trading Corporation in Colombia and Pentafarma & Co. in The Dominican Republic -- will enable Baxa to extend its global reach and expand product promotion in South America and the Caribbean.

"Global markets offer significant potential for growth in Baxa Corporation's key product lines," says Steve Welch, VP of New Business Development. "These new partnerships expand the visibility of the Baxa brand and give us opportunities for sales growth and market expansion. With their focus on pharmacy efficiency and patient safety, Baxa products offer a unique value in healthcare worldwide."

Baxa Corporation provides distributor training and technical support at its headquarters in Englewood, Colorado. Privately held, Baxa Corporation has subsidiaries and sales offices in Canada and the United Kingdom; direct representation in Austria, Belgium, Finland, France, Germany, Luxembourg, The Netherlands and Switzerland; and distribution partners in 35 other countries worldwide.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for fluid handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of fluid medications. Key products include Rapid-Fill(TM) Automated Syringe Fillers, Exacta-Med(R) Oral Dispensers, MicroFuse(R) Syringe Infusers, Repeater(TM) Pharmacy Pumps, and Exacta-Mix(TM) and MicroMacro(TM) Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities -- http://www.baxa.com.

About Magallan Pharma Trading

Magallan is a newly formed company within a group
'/>"/>

SOURCE Baxa Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related medicine technology :

1. Alfacell Corporation to Present at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
2. Millipore Corporation Announces New ReNcell Data from Collaboration with ReNeuron
3. NanoBio Corporation Announces Positive Phase 1 Clinical Results for Topical Treatment for Onychomycosis
4. Alba Therapeutics Corporation Reports Preliminary Phase IIa Clinical Trial Results for AT-1001 for the Treatment of Celiac Disease
5. EpiCept Corporation to Present New NP-1 Data at American Pain Society Meeting
6. Nexavar Significantly Extends Overall Survival by 44% in Liver Cancer Patients
7. MabThera Significantly Extends Survival And Cures More Patients With Aggressive Lymphoma Than Chemotherapy Alone
8. The International Myeloma Foundation Says Data Reported at a Global Medical Meeting in Greece Demonstrates Improved Survival for a Wide Range of Myeloma Patients
9. New Report Looking at Chiral Technologies Analyzes the Global Market Growth Forecasts Driven By Two Very Important Components as Single Isomer Drugs and Single Enantiomer Pharmaceuticals
10. New Study Reveals Limitations of a Complex and Challenging Global Tuberculosis Drug Marketplace
11. Global Rabies Treatment May be Possible with NanoViricides Drugs
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/12/2008)...A, May 12 /- GeoVax Labs, I...HIV/AIDS vaccine development,company, announced to...stock purchase agreement with Fusion Capital Fund ... The Company may sell up to $10 million of its com... a 25-month period after the Securities and,Exchan...
(Date:5/12/2008)...es the Optimal Combination of Scaffolding, Deliver...lity, TEL AVIV, Israel, May 12 /- Me... Mark for its Presillion(TM) CoCr Coronary Stent,...ns with a technologically,innovative flexible clos...he superb scaffolding the unprecedented,balance of...
(Date:5/12/2008)...ELPHIA, May 12 /PRNewswire-USNewswire/ -- GlaxoSmi...ternational Group (BIG), a leading,academic breast...oups, the,Spanish Breast Cancer Cooperative Group ...se III study that will examine the role of TYKERB(...TTO (Neoadjuvant Lapatinib and/or,Trastuzumab Trea...
(Date:5/9/2008)...Fla., May 9 /PRNewswire-USNewswire/ -- Osteoarthri...ition that affects almost 50,million people in the...artilage in bone joints. The novel investigational...al analgesic, provided significant relief,for pati...eated with,placebo, and with fewer gastrointestina...
Breaking Medicine Technology:GeoVax Secures $10 Million Financing Commitment 2GeoVax Secures $10 Million Financing Commitment 3Medinol Receives CE Mark for Presillion(TM) Cobalt Chromium Coronary Stent on Rx System, an Advanced Evolution of the NIR(R) Family of Stents 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 2TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 3TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 4TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 5TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 6TYKERB(R) (Lapatinib) to be Investigated in Landmark Early Breast Cancer Trial 7Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 2Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 3Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 4Results of Phase 3 Study Show Tapentadol IR Relieves Acute Pain and Offers Favorable Gastrointestinal Tolerability Profile 5Mayor Bloomberg Declares March 6 2008 World Glaucoma Day in New York City 12887 1Mayor Bloomberg Declares March 6 2008 World Glaucoma Day in New York City 12887 2Medication Management Systems Names New President and COO 12883 1Medication Management Systems Names New President and COO 12883 2Alzheimers Foundation of America Awards Grants to Local Groups Nationwide 12878 1Alzheimers Foundation of America Awards Grants to Local Groups Nationwide 12878 2Bacteria beware 3A MIT student invents knock out punch for antibiotic resistance 12875 1Bacteria beware 3A MIT student invents knock out punch for antibiotic resistance 12875 2Bacteria beware 3A MIT student invents knock out punch for antibiotic resistance 12875 3Bacteria beware 3A MIT student invents knock out punch for antibiotic resistance 12875 4
...NGLE PARK, N.C. & SHERBROOKE, Quebec--(BUSINES... biopharmaceutical,company developing small molecu... metabolic diseases, today announced positive,resu...elerating,gastric emptying in diabetic patients wi...study were presented at the American,Diabetes Asso...
...INESS WIRE)--Jun 25, 2007 - New data from an,inves... Association,(ADA) 67th Annual Scientific Sessions...via(TM) (sitagliptin) and metformin,demonstrated s...ction in patients with type 2 diabetes. Pancreatic...f the body to produce,insulin, a hormone which pla...
Other Medicine Technology:Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis 2Tranzyme Pharma Presents Initial Phase IIa Data for its Novel,Ghrelin Agonist, TZP-101, in Patients with Diabetic Gastroparesis 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 2An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 3An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 4An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 5An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 6An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 7An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 8An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 9An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 10An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 11An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 12An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 13An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 14An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 15An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 16An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 17An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 18An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 19An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 20An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 21An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 22An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 23An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 24An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 25An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 26An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 27An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 28An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 29An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 30An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 31An Investigational Study Released at ADA Showed that Initial,Combination Therapy with Januvia (sitagliptin) and Metformin Led to,Improvement in Markers of Beta Cell Function in Patients with Type,2 Diabetes 32
(Date:5/12/2008)...Newswire-USNewswire/ -- Michael A.,Sandler, MD, a ...led as,president of the 15,000 member Michigan Sta...meeting of the MSMS House of Delegates on May 3 in...rsity School of Medicine, Doctor,Sandler is senior...t Henry,Ford Hospital and currently serves on the ...
(Date:5/12/2008)...RNewswire-FirstCall/ -- China Yingxia,Internationa..." or "the,Company"), a leading provider in the nut...nufacture and distribution of organic nutritional ...ucts in the People,s Republic,of China ("PRC"), an...riday, May 16, 2008, at 10:00 a.m. EDT, to discuss...
(Date:5/12/2008)...cians from Chongqing Bureau of Health, BLOOMING...thPartners,Institute for Medical Education is host...physicians ever to visit Minnesota. During their,t...tal- and clinic-based,patient care, learn about he...clinical research methodology., "We,re honored ...
(Date:5/12/2008)...ire/ -- Fairbank Farms, a national,ground beef pro...round beef,products produced at its Ashville, N.Y.... BJ,s, and Wilson Farms retail outlets and C&S Who...tain small pieces of hard plastic. All,recalled pr...5/15/08, or a,"Julian date 124" on the package,s l...
Breaking Medicine News(10 mins):Health News:Michael A. Sandler, MD, Installed as President of Michigan State Medical Society 2Health News:China Yingxia International, Inc. Announces Conference Call to Discuss First Quarter 2008 Results 2Health News:First Major Chinese Medical Delegation Visits Minnesota 2Health News:Fairbank Farms Issues Voluntary Recall for Selected Ground Beef Products 2
...st that can detect non-small cell lung cancer (NSC... University of Kentucky. The test is highly accura...several years before they are identified by advanc...ided to partner with 20/20 GeneSystems Inc for the...
...vices in Australia’s Townsville will be revolution...given to the James Cook University (JCU).// A rura...bbott, the Health Minister, at JCU. The University...students to study in Atherton, Cairns, and Mackay....
...ords Science and Technology Committee has issued a...ritain, there would be a severe shortage of food. ...up efforts to collaborate on an international leve...re alternative plans to combat an epidemic should ...
...ated to Food science and consumer acceptance in No...s react differently then do experts to cheese.// T...nsumers were compared with expert dairy assessors....eaction of consumers and quality scores by experts...
Other Medicine News:
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
...laboratory and a worldwide leader in innovative la...extensive test menu of highly complex and unique m...wned by the University of Utah, ARUP Laboratories'...iversity teaching hospitals and children's hospita...
Medicine Products: